Clinical Trials Directory

Trials / Conditions / HER2-low Breast Cancer

HER2-low Breast Cancer

14 registered clinical trials studyying HER2-low Breast Cancer — 12 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingA Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07383506
Cogent Biosciences, Inc.Phase 1
RecruitingHER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC
NCT06830382
Renske Altena—
RecruitingEfficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer
NCT07358182
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University—
RecruitingA Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastati
NCT06957886
Sichuan Baili Pharmaceutical Co., Ltd.Phase 3
Not Yet RecruitingA Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the
NCT06733233
Guangzhou Women and Children's Medical CenterPhase 2
RecruitingTReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
NCT06533826
Ana C Garrido-Castro, MDPhase 2
RecruitingA Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776
Daiichi Sankyo—
RecruitingDisitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
NCT07446452
The First Affiliated Hospital with Nanjing Medical UniversityPhase 2
CompletedStudy of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
NCT06040593
Daiichi Sankyo—
RecruitingPRE-I-SPY Phase I/Ib Oncology Platform Program
NCT05868226
QuantumLeap Healthcare CollaborativePhase 1
RecruitingA Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
NCT05514717
Mersana TherapeuticsPhase 1
RecruitingDistribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer
NCT05466786
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University—
WithdrawnISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With
NCT04602117
QuantumLeap Healthcare CollaborativePhase 1
RecruitingAnalysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low
NCT06877416
Sun Yat-sen University—